A Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Deuremidevir Hydrobromide for Suspension in Hospitalized Infants Infected With Respiratory Syncytial Virus
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Deuremidevir hydrobromide (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Vigonvita Life Sciences
Most Recent Events
- 04 Apr 2025 Planned End Date changed from 1 Jan 2025 to 1 Oct 2025.
- 04 Apr 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Oct 2025.
- 11 Oct 2024 Planned End Date changed from 1 Dec 2024 to 1 Jan 2025.